Journal article
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Francesca Bovis, Tomas Kalincik, Fred Lublin, Gary Cutter, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Murat Terzi, Pierre Grammond, Roberto Bergamaschi, Patrizia Sola Show all
NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
Abstract
OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA to IFN-β-1a in the Com..
View full abstractGrants
Awarded by Italian Ministry of Education, University and Research
Awarded by NIH/NINDS
Funding Acknowledgements
This study was funded by the MSBase Foundation Fellowship. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen, Novartis Pharma, Bayer Schering, Sanofi-Aventis, and BioCSL. This research was supported by the Italian Ministry of Education, University and Research grant PRIN 2017-20178S4EK9. The CombiRx study was funded by NIH/NINDS grant 2U01 NS45719.